Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

4CBY

Design, synthesis, and biological evaluation of potent and selective Class IIa HDAC inhibitors as a potential therapy for Huntington's disease

Summary for 4CBY
Entry DOI10.2210/pdb4cby/pdb
Related4CBT
DescriptorHISTONE DEACETYLASE 4, (1R,2R,3R)-2-[4-(1,3-oxazol-5-yl)phenyl]-N-oxidanyl-3-phenyl-cyclopropane-1-carboxamide, ZINC ION, ... (5 entities in total)
Functional Keywordshydrolase, neurodegeneration, amyotrophic lateral sclerosis, muscle atrophy, class iia histone deacetylase inhibitors, sar, hydroxamic acid, cyclopropanation
Biological sourceHOMO SAPIENS (HUMAN)
Cellular locationNucleus: P56524
Total number of polymer chains4
Total formula weight173010.80
Authors
Primary citationBurli, R.W.,Luckhurst, C.A.,Aziz, O.,Matthews, K.L.,Yates, D.,Lyons, K.A.,Beconi, M.,McAllister, G.,Breccia, P.,Stott, A.J.,Penrose, S.D.,Wall, M.,Lamers, M.,Leonard, P.,Muller, I.,Richardson, C.M.,Jarvis, R.,Stones, L.,Hughes, S.,Wishart, G.,Haughan, A.F.,O'Connell, C.,Mead, T.,McNeil, H.,Vann, J.,Mangette, J.,Maillard, M.,Beaumont, V.,Munoz-Sanjuan, I.,Dominguez, C.
Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
J. Med. Chem., 56:9934-9954, 2013
Cited by
PubMed: 24261862
DOI: 10.1021/jm4011884
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.72 Å)
Structure validation

217705

数据于2024-03-27公开中

PDB statisticsPDBj update infoContact PDBjnumon